drugset / Trial / NCT00112671
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial is studying how well sorafenib works in treating patients with advanced or metastatic cancer of the urinary tract. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Timeline
- Start
- 2005-04
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |